Glitazone fears are alleviated

The diabetes drug rosiglitazone does not necessarily increase cardiovascular risk for type-2 diabetics, claim Canadian researchers.

The findings contrast with a reported 60 per cent increased risk of cardiovascular death associated with the drug, which was widely reported last year.

The latest study involved 193 patients with type-2 diabetes who were randomly assigned to receive either 8mg rosiglitazone or a placebo daily for 12 months.

Researchers found that rosiglitazone helps to lower atherosclerosis rates by lowering lipid levels and inflammatory markers.

No episodes of heart failure or any cardiovascular events were noted during the study.

Lead researcher Dr Oliver Bertrand, from Laval University in Quebec, Canada, told delegates at the ACC in Chicago last week that findings provided reassurance about the safety of rosiglitazone in diabetes.

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in